Donor natural killer cell allorecognition of missing self in haploidentical hernatopoietic transplantation for acute myeloid leukemia: challenging its predictive value

被引:465
|
作者
Ruggeri, Loredana
Mancusi, Antonella
Capanni, Marusca
Urbani, Elena
Carotti, Aiessandra
Aloisi, Teresa
Stern, Martin
Pende, Daniela
Perruccio, Katia
Burchielli, Emanuela
Topini, Fabiana
Bianchi, Erika
Aversa, Franco
Martelli, Massimo F.
Velardi, Andrea
机构
[1] Univ Perugia, Policlin Monteluce, Dept Clin & Expt Med, Div Hematol & Clin Immunol,IRCCS,Fdn Transplantat, I-06122 Perugia, Italy
[2] Ist Nazl Ric Canc, I-16132 Genoa, Italy
关键词
D O I
10.1182/blood-2006-07-038687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We analyzed 112 patients with high-risk acute myeloid leukemia (61 in complete remission (CR]; 51 in relapse), who received human leukocyte-antigen (HLA)-haploidentical transplants from natural killer (NK) alloreactive (n = 51) or non-NK alloreactive donors (n = 61). NK alloreactive donors possessed HLA class 1, killer-cell immunoglobulin-like receptor (KIR) ligand(s) which were missing in the recipients, KIR gene(s) for missing self recognition on recipient targets, and alloreactive NK clones against recipient targets. Transplantation from NK-alloreactive donors was associated with a significantly lower relapse rate in patients transplanted in CR (3% versus 47%) (P > .003), better event-free survival in patients transplanted in relapse (34% versus 6%, P = .04) and in remission (67% versus 18%, P = .02), and reduced risk of relapse or death (relative risk versus non-NK-alloreactive donor, 0.48; 95% Cl, 0.29-0.78; P > .001). In all patients we tested the "missing ligand" model which pools KIR ligand mismatched transplants and KIR ligand-matched transplants from donors possessing KIR(s) for which neither donor nor recipient have HLA ligand(s). Only transplantation from NK-alloreactive donors is associated with a survival advantage.
引用
收藏
页码:433 / 440
页数:8
相关论文
共 50 条
  • [41] Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia
    Cooley, Sarah
    He, Fiona
    Bachanova, Veronika
    Vercellotti, Greg M.
    Defor, Todd E.
    Curtsinger, Julie
    Robertson, Paul Alexander
    Conlon, Kevin C.
    Waldmann, Thomas A.
    McKenna, David H.
    Blazar, Bruce
    Weisdorf, Daniel J.
    Miller, Jeffrey S.
    BLOOD, 2017, 130
  • [42] Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia
    Kawashiri, Anna
    Nakagawa, Shun-ichiro
    Ishiguro, Chisato
    Mochizuki, Kanako
    Maeda, Yoshinobu
    Kurokawa, Toshiro
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2022, 62 (03) : 175 - 180
  • [43] Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
    Kanakry, Christopher G.
    de Lima, Marcos J.
    Luznik, Leo
    SEMINARS IN HEMATOLOGY, 2015, 52 (03) : 232 - 242
  • [44] Haploidentical versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia: Should Donor Type Matter Anymore?
    Solomon, Scott R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (09) : 1540 - 1542
  • [45] Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia
    Bondarenko, Sergey
    Moiseev, Ivan
    Morozova, Elena
    Vlasova, Yulia
    Smirnova, Anna
    Tsvetkov, Nikolai
    Beinarovich, Anastasiya
    Gindina, Tatiana
    Babenko, Elena
    Barkhatov, Ildar
    Alyanskiy, Alexander
    Zubarovskaya, Ludmila
    Kulagin, Alexander
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 191 - 192
  • [46] Haploidentical bone marrow transplantation in a patient with sickle cell disease and acute myeloid leukemia
    Chellapandian, Deepak
    Nicholson, Cameron L.
    PEDIATRIC TRANSPLANTATION, 2020, 24 (01)
  • [47] Clinical Feature and Genetic Alterations in Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia and Myeloid/NK Cell Acute Leukemia
    Nishimura, Akira
    Yokoyama, Kazuaki
    Yamagishi, Chika
    Naruto, Takuya
    Morio, Tomohiro
    Kanai, Akinori
    Matsui, Hirotaka
    Higuchi, Naoko
    Takada, Akiko
    Okuno, Haruna
    Saito, Shoji
    Karakawa, Shuhei
    Kobayashi, Shogo
    Sano, Hideki
    Koike, Takashi
    Hasegawa, Daisuke
    Fujisaki, Hiroyuki
    Hasegawa, Daiichiro
    Koike, Kazutoshi
    Ogawa, Atsushi
    Kinoshita, Akitoshi
    Shiba, Norio
    Miki, Mizuka
    Nakayama, Hideki
    Nakazawa, Yozo
    Imamura, Toshihiko
    Taga, Takashi
    Adachi, Souichi
    Koh, Katsuyoshi
    Manabe, Atsushi
    Taki, Tomohiko
    Ishida, Yasushi
    Tojo, Arinobu
    Takagi, Masatoshi
    BLOOD, 2018, 132
  • [48] Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study
    Cho, Byung-Sik
    Min, Gi-June
    Park, Silvia
    Park, Sung-Soo
    Shin, Seung-Hwan
    Yahng, Seung-Ah
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Kim, Myungshin
    Kim, Yonggoo
    Kim, Hee-Je
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (01) : 98 - 109
  • [49] Association of Ikir-Mismatching and Donor Akirs with Better Outcomes in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
    Zhang, Yu
    Chen, Shaozhen
    Ren, Jinhua
    Luo, Xiaofeng
    Hu, Jianda
    Yang, Ting
    BLOOD, 2021, 138
  • [50] Alloreactive natural killer cells for the treatment of acute myeloid leukemia: from stem cell transplantation to adoptive immunotherapy
    Ruggeri, Loredana
    Parisi, Sarah
    Urbani, Elena
    Curti, Antonio
    FRONTIERS IN IMMUNOLOGY, 2015, 6